Taurolidine

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

Retrieved on: 
Monday, April 15, 2024
FDA, CMS, Risk, Safety, CLS, Heparin, Food, Kidney failure, HD, Incidence, Patient, Medicare, Taurolidine, CVC, HCPCS, Medical device

We are proud to provide an option for adult patients who face the risk of CRBSIs.

Key Points: 
  • We are proud to provide an option for adult patients who face the risk of CRBSIs.
  • We look forward to expanding the availability of DefenCath to the outpatient setting later this year.”
    The commencement of U.S. outpatient commercialization of DefenCath is planned for July 1, 2024.
  • If exposure to either of the above occurs, discontinue use of DefenCath and institute appropriate supportive measures.
  • To report any safety concerns including suspected adverse reactions, contact CorMedix Inc. at 1-888-424-6345 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

Retrieved on: 
Monday, April 8, 2024
Dialysis, Antibiotic, CVC, Infection, Patient, NDA, Taurolidine, Heparin, ARC, FDA, Health, Medical device

CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and expects to begin commercialization of the product in the inpatient setting on April 15th.

Key Points: 
  • CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and expects to begin commercialization of the product in the inpatient setting on April 15th.
  • CorMedix is committed to building meaningful long-term relationships with dialysis providers that are dedicated to innovation and infection reduction.
  • ARC Dialysis, a Miami-based medium-sized dialysis organization, provides inpatient dialysis services to approximately 100 inpatient facilities, and is the operator of 18 outpatient dialysis units throughout Florida.
  • “This agreement with CorMedix for the adoption of DefenCath reinforces our commitment to innovation and patient care, and we are proud of the reputation we’ve established for ourselves as a leading dialysis provider in the southeast United States,” says Fred Dumenigo, CEO of ARC Dialysis.

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

Retrieved on: 
Wednesday, October 11, 2023
Antifungal, Fluconazole, Bloodstream infections, Candida auris, Taurolidine, Pharmaceutical industry

The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.

Key Points: 
  • The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.
  • Taurolidine exhibited in vitro antimicrobial activity against all C. auris strains and isolates regardless of geographic source, year of isolation, or clade.
  • There was no evidence that taurolidine activity was affected by resistance to amphotericin B or fluconazole.
  • The abstract is available through the IDWeek conference website.

CorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12

Retrieved on: 
Wednesday, July 28, 2021
Medicine, Medical specialties, Antibiotics, Taurolidine, Health care, Intravenous fluids, Catheter lock solution, Parenteral nutrition, Medication, Oncology

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Key Points: 
  • CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
  • CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients.
  • It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels.
  • The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

CorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference

Retrieved on: 
Wednesday, June 9, 2021
Medicine, Medical specialties, Antibiotics, Taurolidine, Health care, Intravenous fluids, Catheter lock solution, Parenteral nutrition, Medication, Oncology

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Key Points: 
  • CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
  • CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients.
  • It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels.
  • The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Medicine, Antibiotics, Taurolidine, Clinical medicine, Intravenous fluids, Catheter lock solution, Parenteral nutrition, Medication, Oncology

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Key Points: 
  • CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
  • CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients.
  • It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels.
  • The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

CorMedix Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13

Retrieved on: 
Wednesday, May 5, 2021
Antibiotics, Medical specialties, Taurolidine, Medicine, Chemistry, Intravenous fluids, Catheter lock solution, Parenteral nutrition, Hydrogel, Catheter

b'CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Key Points: 
  • b'CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
  • QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA.
  • CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients.
  • It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels.

CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Medical specialties, Medicine, Health care, Antibiotics, Taurolidine, Parenteral nutrition

BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference taking place on April 12 15, 2021.

Key Points: 
  • BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference taking place on April 12 15, 2021.
  • CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
  • CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients.
  • The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30

Retrieved on: 
Tuesday, March 23, 2021
Medical specialties, Medicine, Antibiotics, Taurolidine, Health, Intravenous fluids, Catheter lock solution, Parenteral nutrition, Medication, Oncology

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Key Points: 
  • CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
  • CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients.
  • It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels.
  • The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

CorMedix Inc. to Host Regulatory Update Conference Call

Retrieved on: 
Monday, March 8, 2021
Medical specialties, Medicine, Antibiotics, Taurolidine, Health, Intravenous fluids, Catheter lock solution, Parenteral nutrition, Medication, Oncology

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Key Points: 
  • CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
  • CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients.
  • It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels.
  • The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.